These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26678887)

  • 21. Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.
    Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
    Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
    Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
    Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis.
    Li YP; Pang J; Gao S; Bai PY; Wang WD; Kong P; Cui Y
    Tumour Biol; 2017 Jun; 39(6):1010428317706206. PubMed ID: 28621237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CXCL12/CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma.
    Wang DF; Lou N; Zeng CG; Zhang X; Chen FJ
    Ai Zheng; 2009 Feb; 28(2):154-8. PubMed ID: 19550128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.
    Weixler B; Renetseder F; Facile I; Tosti N; Cremonesi E; Tampakis A; Delko T; Eppenberger-Castori S; Tzankov A; Iezzi G; Kettelhack C; Soysal SD; von Holzen U; Spagnoli GC; Terracciano L; Tornillo L; Droeser RA; Däster S
    Cell Oncol (Dordr); 2017 Dec; 40(6):609-619. PubMed ID: 28936810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study.
    Du C; Yao Y; Xue W; Zhu WG; Peng Y; Gu J
    BMJ Open; 2014; 4(8):e005012. PubMed ID: 25232565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma.
    Mazur G; Gębura K; Gieryng A; Butrym A; Wróbel T; Bogunia-Kubik K
    Cytokine; 2013 Oct; 64(1):422-6. PubMed ID: 23711392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis.
    Cui K; Zhao W; Wang C; Wang A; Zhang B; Zhou W; Yu J; Sun Z; Li S
    J Surg Res; 2011 Nov; 171(1):143-50. PubMed ID: 20462600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association of CXCR4 and SDF-1alpha with organ-specific metastasis of nasopharyngeal carcinoma].
    Luo HN; Li XP; Liu X; Zhang GH; Liu YL
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):260-4. PubMed ID: 19615279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
    Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
    Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.
    Wagner PL; Moo TA; Arora N; Liu YF; Zarnegar R; Scognamiglio T; Fahey TJ
    Ann Surg Oncol; 2008 Oct; 15(10):2833-41. PubMed ID: 18696160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of CXCL12 and CXCR4 in pT3-stage gastric cancer does not correlate with peritoneal metastasis.
    Tsuboi K; Kodera Y; Nakanishi H; Ito S; Mochizuki Y; Nakayama G; Koike M; Fujiwara M; Yamamura Y; Nakao A
    Oncol Rep; 2008 Nov; 20(5):1117-23. PubMed ID: 18949410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma].
    Wei M; Liang LZ; Zhang CQ; Xiong Y; Zhang Y; Shen Y; Li JQ
    Ai Zheng; 2007 Mar; 26(3):298-302. PubMed ID: 17355795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.
    Guembarovski AL; Guembarovski RL; Hirata BKB; Vitiello GAF; Suzuki KM; Enokida MT; Watanabe MAE; Reiche EMV
    Mol Biol Rep; 2018 Oct; 45(5):741-750. PubMed ID: 29926386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
    Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.
    Giessen-Jung C; Nagel D; Glas M; Spelsberg F; Lau-Werner U; Modest DP; Schulz C; Heinemann V; Di Gioia D; Stieber P
    Tumour Biol; 2015 Sep; 36(10):7897-906. PubMed ID: 25953265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.